Intercept's Cirrhosis Endpoint Gets FDA Panel Nod For Accelerated Approval

But advisory committee members echo FDA concerns about sponsor's ability to complete placebo-controlled confirmatory trial for the obeticholic acid product and weigh changes in enrollment criteria for ongoing study.